S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Billionaires Are Now FLOODING Into Gold (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
How to profit from the new boom in gold (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Billionaires Are Now FLOODING Into Gold (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
How to profit from the new boom in gold (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Billionaires Are Now FLOODING Into Gold (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
How to profit from the new boom in gold (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Billionaires Are Now FLOODING Into Gold (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
How to profit from the new boom in gold (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes

Novan (NOVN) Competitors

$0.0008
0.00 (0.00%)
(As of 02/23/2024 ET)

NOVN vs. NTBL, CMND, NBSE, CYTO, LMDX, SNOA, QLGN, APVO, PCSA, and ARAV

Should you be buying Novan stock or one of its competitors? The main competitors of Novan include Notable Labs (NTBL), Clearmind Medicine (CMND), NeuBase Therapeutics (NBSE), Altamira Therapeutics (CYTO), LumiraDx (LMDX), Sonoma Pharmaceuticals (SNOA), Qualigen Therapeutics (QLGN), Aptevo Therapeutics (APVO), Processa Pharmaceuticals (PCSA), and Aravive (ARAV). These companies are all part of the "pharmaceutical preparations" industry.

Novan vs.

Novan (NASDAQ:NOVN) and Notable Labs (NASDAQ:NTBL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

14.5% of Novan shares are held by institutional investors. Comparatively, 1.0% of Notable Labs shares are held by institutional investors. 1.3% of Novan shares are held by insiders. Comparatively, 6.1% of Notable Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novan has higher revenue and earnings than Notable Labs. Notable Labs is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novan$24.71M0.00-$31.31M-$1.320.00
Notable Labs$660K4.14-$32.30M-$3.63-0.34

In the previous week, Notable Labs had 2 more articles in the media than Novan. MarketBeat recorded 3 mentions for Notable Labs and 1 mentions for Novan. Novan's average media sentiment score of 0.00 beat Notable Labs' score of -0.08 indicating that Novan is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novan
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Notable Labs
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Novan has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Notable Labs has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Novan presently has a consensus price target of $8.00, suggesting a potential upside of 999,900.00%. Notable Labs has a consensus price target of $9.00, suggesting a potential upside of 631.71%. Given Novan's higher probable upside, analysts clearly believe Novan is more favorable than Notable Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novan
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Notable Labs
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Novan received 236 more outperform votes than Notable Labs when rated by MarketBeat users. However, 100.00% of users gave Notable Labs an outperform vote while only 57.45% of users gave Novan an outperform vote.

CompanyUnderperformOutperform
NovanOutperform Votes
239
57.45%
Underperform Votes
177
42.55%
Notable LabsOutperform Votes
3
100.00%
Underperform Votes
No Votes

Notable Labs has a net margin of 0.00% compared to Novan's net margin of -128.61%. Notable Labs' return on equity of -39.30% beat Novan's return on equity.

Company Net Margins Return on Equity Return on Assets
Novan-128.61% -700.28% -39.58%
Notable Labs N/A -39.30%-30.39%

Summary

Notable Labs beats Novan on 10 of the 18 factors compared between the two stocks.


Get Novan News Delivered to You Automatically

Sign up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NOVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NOVN vs. The Competition

MetricNovanPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$22,000.00$6.77B$5.15B$7.54B
Dividend YieldN/A2.78%2.87%3.86%
P/E Ratio0.009.40173.1015.36
Price / Sales0.00250.153,081.8969.42
Price / CashN/A18.7099.4254.97
Price / Book0.004.604.414.60
Net Income-$31.31M$156.45M$114.54M$207.21M
7 Day PerformanceN/A0.97%0.88%-1.09%
1 Month PerformanceN/A9.33%7.03%3.27%
1 Year PerformanceN/A3.97%10.14%5.59%

Novan Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NTBL
Notable Labs
1.8816 of 5 stars
$1.17
-3.3%
$9.00
+669.2%
N/A$2.60M$660,000.00-0.3213News Coverage
Positive News
Gap Up
CMND
Clearmind Medicine
0 of 5 stars
$1.46
-3.9%
N/A-98.2%$2.47MN/A0.00N/ANews Coverage
NBSE
NeuBase Therapeutics
0 of 5 stars
$0.66
-2.9%
N/A-84.5%$2.46MN/A-0.0937
CYTO
Altamira Therapeutics
0 of 5 stars
$1.79
-3.8%
N/A-96.4%$2.83M$320,000.000.0016Gap Down
LMDX
LumiraDx
0 of 5 stars
$0.01
flat
$1.45
+16,192.1%
-99.2%$2.84M$126.52M-0.011,210Gap Up
SNOA
Sonoma Pharmaceuticals
2.3734 of 5 stars
$0.16
-6.1%
$3.25
+1,996.8%
-89.2%$2.42M$13.27M-0.169Positive News
Gap Down
QLGN
Qualigen Therapeutics
0 of 5 stars
$0.47
flat
N/A-55.5%$2.41M$4.98M0.0031News Coverage
Gap Up
High Trading Volume
APVO
Aptevo Therapeutics
0 of 5 stars
$0.15
flat
N/A-93.3%$2.86M$3.11M0.0045Analyst Report
News Coverage
PCSA
Processa Pharmaceuticals
2.5032 of 5 stars
$2.34
-5.6%
$70.00
+2,891.5%
-84.3%$2.88MN/A-0.1015
ARAV
Aravive
3.6704 of 5 stars
$0.04
flat
$12.25
+30,448.6%
N/A$2.95M$6.99M-0.0423

Related Companies and Tools

This page (NASDAQ:NOVN) was last updated on 2/25/2024 by MarketBeat.com Staff